OS Therapies, Inc. (OSTX)
1.60
+0.06
(+3.90%)
USD |
NYAM |
Dec 18, 16:00
1.63
+0.03
(+1.88%)
Pre-Market: 07:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 56.34M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -60.88% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 15.49 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Grasonville, MD. |
| URL | http://www.ostherapies.com |
| Investor Relations URL | N/A |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 17, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Grasonville, MD. |
| URL | http://www.ostherapies.com |
| Investor Relations URL | N/A |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 17, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |